A detailed history of E Fund Management Co., Ltd. transactions in Novavax Inc stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 24,121 shares of NVAX stock, worth $204,304. This represents 0.02% of its overall portfolio holdings.

Number of Shares
24,121
Previous 15,904 51.67%
Holding current value
$204,304
Previous $201,000 51.24%
% of portfolio
0.02%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$10.71 - $17.11 $88,004 - $140,592
8,217 Added 51.67%
24,121 $304,000
Q2 2024

Aug 12, 2024

SELL
$3.89 - $20.97 $247,442 - $1.33 Million
-63,610 Reduced 80.0%
15,904 $201,000
Q1 2024

May 13, 2024

SELL
$3.76 - $6.02 $26,485 - $42,404
-7,044 Reduced 8.14%
79,514 $380,000
Q4 2023

Feb 06, 2024

BUY
$4.8 - $7.67 $170,788 - $272,906
35,581 Added 69.8%
86,558 $415,000
Q3 2023

Nov 13, 2023

SELL
$6.81 - $9.74 $60,030 - $85,858
-8,815 Reduced 14.74%
50,977 $369,000
Q2 2023

Aug 11, 2023

BUY
$6.67 - $9.52 $3,741 - $5,340
561 Added 0.95%
59,792 $444,000
Q1 2023

May 11, 2023

BUY
$5.76 - $12.48 $193,708 - $419,702
33,630 Added 131.36%
59,231 $410,000
Q4 2022

Feb 14, 2023

BUY
$8.86 - $25.04 $93,774 - $265,023
10,584 Added 70.48%
25,601 $263,000
Q3 2022

Nov 14, 2022

BUY
$18.2 - $76.12 $77,113 - $322,520
4,237 Added 39.3%
15,017 $273,000
Q2 2022

Aug 15, 2022

BUY
$36.28 - $75.29 $257,733 - $534,860
7,104 Added 193.25%
10,780 $554,000
Q1 2022

May 12, 2022

BUY
$69.73 - $142.9 $208,701 - $427,699
2,993 Added 438.21%
3,676 $271,000
Q1 2021

May 12, 2021

BUY
$112.98 - $319.93 $77,165 - $218,512
683 New
683 $123,000

Others Institutions Holding NVAX

About NOVAVAX INC


  • Ticker NVAX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 78,215,104
  • Market Cap $662M
  • Description
  • Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; Nan...
More about NVAX
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.